Project Grant R44EY037156
Award Date 9/15/25
Completion Date 8/31/27
Dollars Obligated $871K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Research Triangle Park, Durham, NC, USA
Similar Awards
- This Project Grant award of $310,952 from the National Eye Institute's Vision Research program, awarded on August 1, 2025, supports the development of a novel gene therapy approach by Bedrock Therapeutics, Inc., a small disadvantaged biotech company located in Raleigh, North Carolina. The goal is to create an effective and practical treatment for neovascular age-related macular degeneration (NAMD), the leading cause of blindness in people over 50. Bedrock's strategy combines an...
- The National Eye Institute (NEI) awarded a $312,239 Project Grant under the Vision Research federal grant program (CFDA 93.867) to Shift Pharmaceuticals Holdings, Inc. for the development of an antisense oligonucleotide (ASO) therapeutic to inhibit retinoic acid signaling and mitigate vision loss in retinitis pigmentosa and age-related macular degeneration. The project aims to create a targeted ASO therapy that can block the production of retinoic acid receptors at the cellular level within...
- This federal Project Grant award from the National Eye Institute (NEI) at the Department of Health and Human Services provides $1,850,000 in funding to Biostrategies LC to advance the development of BIOS-GM1, a novel gene therapy and enzyme replacement therapy for the treatment of GM1 gangliosidosis. The grant supports Biostrategies' efforts to complete IND-enabling studies for BIOS-GM1, which combines an adeno-associated virus (AAV) gene therapy approach with a lectin-enhanced enzyme delivery...
- This Project Grant award from the National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867) is funding research to develop an innovative gene therapy approach using self-amplifying and self-splicing RNA technologies. The $346,500 award, spanning September 2024 to September 2026, aims to evaluate the longevity, immunogenicity, and potential in vivo side effects of this novel mRNA-based therapy for treating inherited retinal dystrophies. The award recipient, The...
- This $1,369,974 Project Grant was awarded on September 15, 2025 by the National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867) to the West Virginia University Research Corporation (WVURC). The funding supports a 3-year research project to investigate therapies for defects in protein networks essential for the development of photoreceptor outer segments, a key component of photoreceptor neurons responsible for vision. The research aims to identify an optimal...
- The National Eye Institute (NEI), under the federal Vision Research grant program (CFDA 93.867), awarded a $300,016 project grant to Fannin Partners LLC, a Houston-based biomedical research company, to develop SCG3 raptamers as a novel targeted therapy for wet age-related macular degeneration (AMD). Wet AMD is a leading cause of vision loss, affecting over 1.25 million individuals in the United States. The project aims to create an aptamer-based treatment that targets secretogranin III (SCG3), a...
- This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides $306,814 to Piximune, Inc. to develop an antibody-based, gene-agnostic treatment for inherited retinal degeneration, such as retinitis pigmentosa. The proposed approach aims to augment natural mechanisms that eliminate toxic cellular debris from dead and dying photoreceptor cells, thereby protecting surrounding functional cells and preventing secondary retinal damage independent of the causal...
- The National Eye Institute (NEI) awarded a $249,000 project grant to the Trustees of Indiana University, doing business as Indiana University, to investigate the recovery of retinal function following gene therapy for inherited retinal degenerations. The project, titled "The Contribution of Plasticity to the Recovery of Retinal Function Following Gene Therapy," aims to elucidate the fundamental mechanisms that enable the retina to establish functional connections after gene therapy....
- The National Eye Institute (NEI) awarded a $431,750 Project Grant to the University of California, Irvine (UCI) to support research on "Amplified Femtosecond Laser Permeabilization and Poration for Nonviral Corneal Gene Delivery". The goal is to develop a novel, femtosecond laser-based approach to overcome barriers to topical gene therapy delivery to the cornea. This research aims to create microchannels through the corneal epithelium to enhance transepithelial diffusion and use...
- The National Institutes of Health's National Eye Institute awarded Greffex Inc. a $902,455 Project Grant under the Vision Research program (CFDA 93.867) to develop an Usher gene therapy. Greffex will leverage its fully deleted adenoviral vector platform, which can accommodate payloads up to 33kb, to deliver a full-length Usher Syndrome Type 2A coding cDNA to photoreceptors. This aims to establish an efficient gene transfer method to treat Usher Syndrome Type 2, the leading genetic cause of...